Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 6/20 | 0.49 |
| ▸ | CKS1B | P61024 | 4/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976763 | 0.84 | CYP17A1 (0.45) | TOP1PIK3CDCOMTCCR1CCR8 | |
| SCHEMBL17264581 | 0.84 | CKS1B (0.49) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL9976735 | 0.82 | TOP1 (0.42) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL913533 | 0.81 | CCR1 (0.58) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL29441295 | 0.81 | CCR1 (0.58) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL9976748 | 0.81 | CCR1 (0.48) | PIK3CDCCR1CCR8L3MBTL1MMP2 | |
| SCHEMBL14478630 | 0.81 | TOP1 (0.45) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL12761837 | 0.80 | TOP1 (0.45) | TOP1CKS1BSKP2GLO1CCR1 | |
| SCHEMBL20726711 | 0.80 | CCR1 (0.49) | TOP1CKS1BSKP2GLO1PIK3CD | |
| SCHEMBL12830771 | 0.80 | TOP1 (0.35) | TOP1CKS1BSKP2GLO1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877354-B2 | Heterocyclic compound and organic light-emitting device using the same | CANON KABUSHIKI KAISHA (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120153270-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | ORC3, CYP1A1, CRY1 | TOP1 1962/4885CKS1B 1625/4885SKP2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.